{"url_path":"/sec/rgbp/8-k/2026-07-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1589150/0001493152-26-033364-index.html","accession_number":"0001493152-26-033364","cik":"0001589150","ticker":"RGBP","issuer_name":"Regen BioPharma Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1589150/0001493152-26-033364-index.html","primary_entity_key":"0001589150","primary_entity_name":"Regen BioPharma Inc"},"word_count":96,"has_tables":true,"body_markdown":"**Item\n9.01. Financial Statements and Exhibits.**\n\n \n\n**Exhibit\nNo.**\n \n**Description\nof Exhibit**\n\n3(i)\n \n[Certificate of Designations](ex3-i.htm)\n\n16.1\n \n[Letter from BCRG](ex16-1.htm)\n\n10.01\n \n[Settlement and Mutual Release Agreement](ex10-01.htm)\n\n104\n \nCover Page Interactive Data File (embedded\nwithin the Inline XBRL document)\n\n \n\nPage 3 of 4\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**REGEN\nBIOPHARMA, INC.**\n\n \n \n \n\nDated:\nJuly 15, 2026\n*By:*\n*/s/\nDavid Koos*\n\n \nName:\nDavid\nKoos\n\n \nTitle:\nChairman\nand Chief Executive Officer\n\n \n\nPage 4 of 4"}